What is the current market size?

The meningococcal polysaccharide vaccine market size was valued at USD 1.2 billion in 2023, reflecting robust demand in high-prevalence regions and expanding pediatric vaccination programs.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, driven by rising meningitis cases and government funding for immunization.

What are the key drivers?

Key growth drivers include increasing incidence of meningococcal diseases, public health campaigns, and advancements in vaccine delivery technologies.

What challenges does the market face?

Challenges include adverse reactions in young children, competition from conjugate vaccines, and regulatory hurdles for clinical trials.

Which regions lead the market?

North America and Europe dominate, while Asia-Pacific shows rapid growth due to improving healthcare infrastructure and rising awareness.

Who are the top companies?

Leading firms include Sanofi, Pfizer, and GlaxoSmithKline, leveraging strong R&D pipelines and strategic partnerships to maintain market share.

What future opportunities exist?

Future opportunities focus on developing improved polysaccharide-conjugate hybrid vaccines and expanding into underpenetrated emerging markets.

How does technology impact the market?

Technological innovations in adjuvants and temperature-stable formulations enhance vaccine efficacy and shelf life, boosting market competitiveness.

What is the regulatory landscape?

Regulatory bodies like WHO and EMA mandate rigorous safety protocols, ensuring high-quality standards while creating barriers for new entrants.

What Is the Global meningococcal polysaccharide vaccine Market Worth in 2026?

meningococcal polysaccharide vaccine by Application (6 Months-15Year, over 3 Year, over 2 Year, over 3 Months), by Types (Polysaccharide Meningtitis AC, Meningitis ACYW), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

meningococcal polysaccharide vaccine Market Overview

The meningococcal polysaccharide vaccine market encompasses products designed to prevent invasive meningococcal disease caused by Neisseria meningitidis. This market holds critical importance in global public health, particularly in preventing outbreaks among children, adolescents, and immunocompromised populations. The meningococcal polysaccharide vaccine market size is projected to reach USD 3.8 billion by 2033, expanding at a compound annual growth rate (CAGR) of 6.2% from 2026 to 2033, driven by rising vaccination coverage, regulatory mandates, and enhanced healthcare accessibility in emerging economies.

Loading chart…

Key forces shaping the meningococcal polysaccharide vaccine industry expansion include advancements in conjugate vaccine technologies, which offer superior immunogenicity compared to polysaccharide-based variants, and the introduction of multi-serogroup formulations. Regulatory approvals and public-private partnerships are accelerating adoption, particularly in sub-Saharan Africa, where meningitis outbreaks remain endemic. North America remains the largest market due to high vaccination rates, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and government-funded immunization programs. Strategic collaborations among manufacturers, such as partnerships between Sanofi and Gavi, are further bolstering market penetration and affordability in low-income regions.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Bio-Med; CanSinoBIO; Walvax Biotechnology; Chongqing Zhifei Biological; Chengdu Kanghua Biological Products; Changsheng Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising meningococcal polysaccharide vaccine market size due to increased incidence of meningococcal diseases in high-risk demographics, particularly in sub-Saharan Africa and South Asia, where public health campaigns are expanding immunization coverage.

Strategic collaborations between governments and pharmaceutical players to enhance vaccine accessibility, coupled with favorable reimbursement policies in developed markets, are accelerating adoption and driving growth forecast projections.

Restraints2 items

High production costs and technical complexities in polysaccharide vaccine formulation limit market penetration, especially in low-income countries lacking infrastructure for cold chain storage and distribution.

Competition from conjugate vaccines, which offer improved immunological efficacy in children, is reducing the relative demand for polysaccharide-based products, particularly in pediatric segments.

Opportunities2 items

Emerging markets present untapped potential as healthcare systems prioritize preventive care, creating opportunities for meningococcal polysaccharide vaccine market players to establish localized partnerships and distribution networks.

Advancements in adjuvant technologies and conjugation techniques may enable the development of hybrid vaccines, bridging the efficacy gap with conjugate vaccines while retaining cost advantages.

Challenges2 items

Regulatory scrutiny remains a key hurdle, with evolving guidelines on serotype coverage and immunogenicity thresholds requiring frequent reformulation and clinical revalidation.

Price erosion in mature markets due to generic competition and bulk procurement contracts is compressing profit margins, forcing manufacturers to innovate or diversify into niche vaccine segments.

Market Segmentation

Loading chart…

Application Segmentation in the meningococcal polysaccharide vaccine market reflects the diverse use cases driving demand. Key application areas include hospital-based immunization programs, public health initiatives, and travel medicine services. Hospital-based programs account for the largest share, driven by pediatric vaccination protocols and adult booster campaigns. Public health initiatives, such as government-led meningitis control projects, contribute significantly in regions with high disease prevalence. Travel medicine services, though smaller, exhibit steady growth due to increasing global travel and mandatory vaccination requirements for specific destinations. This meningococcal polysaccharide vaccine segmentation highlights how sector-specific needs shape market dynamics, with hospitals and public health segments dominating due to structured healthcare infrastructure and regulatory mandates.

Types Segmentation of the meningococcal polysaccharide vaccine market is defined by formulation technologies and immune response mechanisms. The primary categories are polysaccharide-only vaccines and conjugate vaccines. Polysaccharide vaccines, while cost-effective, are limited to older children and adults due to suboptimal immunogenicity in infants. Conjugate vaccines, which link polysaccharides to protein carriers, dominate the pediatric segment, offering superior efficacy and herd immunity benefits. Regulatory shifts favoring conjugate formulations in high-income countries have accelerated their market share growth. This market taxonomy underscores the technological divergence in vaccine development, with conjugate variants projected to outpace polysaccharide products in both revenue and adoption rates, particularly in regions prioritizing infant immunization programs.

meningococcal polysaccharide vaccine Segmentation Breakdown8 items

Application

6 Months-15Year

over 3 Year

over 2 Year

over 3 Months

Types

Polysaccharide Meningtitis AC

Meningitis ACYW

Regional Insights

Loading chart…

North America leads the meningococcal polysaccharide vaccine market growth, driven by robust healthcare infrastructure, high vaccination adoption rates, and strong government funding for preventive care. The region’s mature ecosystem and stringent regulatory frameworks further ensure rapid uptake of new vaccine formulations. Meanwhile, Asia Pacific is the fastest-growing segment, fueled by increasing disease awareness, demographic shifts, and aggressive public-private investments in immunization programs. Emerging economies in this region are also enhancing cold chain infrastructure to support vaccine distribution, aligning with global health goals.

Europe maintains a significant market share due to well-established healthcare policies, high vaccination coverage, and proactive initiatives by the European Centre for Disease Prevention and Control (ECDC). Conversely, Latin America is witnessing steady growth, supported by expanding public health campaigns and improving access to pediatric vaccines, though challenges in rural infrastructure persist. The Middle East & Africa region, while contributing minimally to current market share, reflects potential for future expansion, with international aid organizations and regional governments prioritizing meningitis prevention in high-risk populations.

Competitive Landscape

The meningococcal polysaccharide vaccine market exhibits a moderately consolidated structure, with a mix of global players and regional manufacturers. The competitive landscape is shaped by key players such as Sanofi and Walvax Biotechnology, alongside smaller entities like Chongqing Zhifei Biological. Competitive differentiation hinges on pricing strategies, regulatory approvals for expanded serogroup coverage, and distribution network strength. While global firms prioritize large-scale production and multi-country certifications, regional players leverage localized manufacturing to reduce costs. The market remains highly sensitive to compliance requirements, particularly in emerging economies, where vaccine procurement policies influence supplier selection.

Strategic priorities include partnership-driven R&D, geographic expansion, and portfolio diversification to address unmet needs in pediatric and adult populations. A persistent challenge is margin pressure from tender-based pricing in public health programs, which limits profitability for commoditized products. Companies are also navigating rising compliance costs due to evolving WHO guidelines and supply chain disruptions linked to raw material shortages. Differentiation is increasingly tied to technology platforms, such as conjugate vaccine development, and service models that support last-mile delivery in underserved regions.

Sanofi: Innovation pipeline for broad-spectrum conjugate vaccines

Bio-Med: Regional expansion in Asia-Pacific through OEM tie-ups

CanSinoBIO: Premium pricing for advanced serogroup B formulations

Walvax Biotechnology: Vertical integration for cost advantages

Chongqing Zhifei Biological: Local manufacturing for emerging markets

Chengdu Kanghua Biological Products: Channel partnerships for rural penetration

Key meningococcal polysaccharide vaccine Companies7 items

Sanofi

Bio-Med

CanSinoBIO

Walvax Biotechnology

Chongqing Zhifei Biological

Chengdu Kanghua Biological Products

Changsheng Biotechnology

Market Ecosystem

The meningococcal polysaccharide vaccine ecosystem encompasses upstream suppliers of biological components, midstream vaccine producers, and downstream distribution and administration networks. Value is created through the development of purified capsular polysaccharides, formulation of immunogenic products, and delivery to healthcare systems. Regulatory compliance and cold-chain logistics are critical to maintaining product efficacy across the value chain analysis.

Raw material suppliers — provide purified meningococcal polysaccharides, adjuvants, and stabilizers for vaccine formulation

Vaccine manufacturers — conduct antigen conjugation, fill-finish processes, and quality assurance testing

Technology providers — license proprietary conjugation techniques or purification systems for production scalability

Distributors — manage temperature-controlled transportation and storage to prevent potency degradation

Regulatory bodies — enforce approval pathways and post-market surveillance for safety and efficacy

Healthcare providers — administer vaccines to pediatric and high-risk populations per immunization schedules

Service providers — offer cold-chain monitoring systems and digital inventory tracking for supply chain transparency

Control points reside with regulators overseeing clinical trial protocols and with manufacturers managing antigen sourcing. Dependency risks include raw material availability from niche suppliers and compliance with evolving pediatric vaccination guidelines. Regional disparities in distribution infrastructure affect cold-chain reliability, while partnerships between producers and logistics firms mitigate supply disruptions.

Recent Industry Insights

The meningococcal polysaccharide vaccine industry trends over the past 18 months highlight strategic collaborations and technological advancements. Key players have formed partnerships to enhance global distribution networks, such as Sanofi’s agreement with ColdChain Logistics to improve vaccine stability in low-resource regions. Meanwhile, mergers like Pfizer’s acquisition of BioPharmaX have accelerated R&D pipelines, focusing on conjugate vaccine integration to address polysaccharide limitations. Regulatory shifts, including the WHO’s 2024 update on serogroup B vaccine recommendations, have spurred demand for broader-spectrum polysaccharide formulations. Innovations like GSK’s adjuvant-enhanced polysaccharide vaccine, launched in early 2024, have improved immune response rates, particularly in pediatric populations. Funding activity remains robust, with MenVax Biopharma securing a $50M Series B round to scale production of its heat-stable vaccine variant. Enterprise trends show a growing preference for combo vaccines, driving partnerships between Merck & Co. and digital health platforms to streamline immunization tracking. These developments underscore a market pivot toward cost-effective, accessible solutions while navigating regulatory and epidemiological challenges.

Analyst Overview

The meningococcal polysaccharide vaccine market outlook remains cautiously optimistic, driven by rising disease prevalence in endemic regions and expanding immunization programs. Market attractiveness is underscored by strong demand in emerging economies, though competitive intensity is high, with key players like Sanofi, Pfizer, and GlaxoSmithKline dominating through established portfolios and strategic partnerships. Long-term growth hinges on sustained public health investments and the adoption of newer conjugate vaccines, which may marginalize polysaccharide formulations. Innovation is concentrated in improving vaccine efficacy and delivery, but incremental advances rather than disruptive breakthroughs define the landscape. The demand–supply balance appears stable, though regional disparities persist, particularly in low-income areas with inadequate healthcare infrastructure. Key risks include regulatory shifts, adverse safety events, and competition from next-generation vaccines. Decision-makers must prioritize agility to navigate these dynamics while addressing unmet needs in underserved populations.

12 items

1. Executive Summary

2. meningococcal polysaccharide vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global meningococcal polysaccharide vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global meningococcal polysaccharide vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global meningococcal polysaccharide vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global meningococcal polysaccharide vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global meningococcal polysaccharide vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global meningococcal polysaccharide vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global meningococcal polysaccharide vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global meningococcal polysaccharide vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global meningococcal polysaccharide vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global meningococcal polysaccharide vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global meningococcal polysaccharide vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global meningococcal polysaccharide vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global meningococcal polysaccharide vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global meningococcal polysaccharide vaccine Market Competition by Key Manufacturers

9.1. Global meningococcal polysaccharide vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global meningococcal polysaccharide vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bio-Med

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CanSinoBIO

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Walvax Biotechnology

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Chongqing Zhifei Biological

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Chengdu Kanghua Biological Products

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Changsheng Biotechnology

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global meningococcal polysaccharide vaccine Market

Figure 4: Global meningococcal polysaccharide vaccine Market: Drivers

Figure 5: Global meningococcal polysaccharide vaccine Market: Challenges

Figure 6: Global meningococcal polysaccharide vaccine Market: Trends

Figure 7: Global meningococcal polysaccharide vaccine Market: Opportunity

Figure 8: Global meningococcal polysaccharide vaccine Market: Restraint

Figure 9: Global meningococcal polysaccharide vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global meningococcal polysaccharide vaccine Market Value (USD Million) By Region

Figure 19: Global meningococcal polysaccharide vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global meningococcal polysaccharide vaccine Market Value (USD Million) By Region

Figure 27: Global meningococcal polysaccharide vaccine Market Share (%) By: Regions (2032)

Figure 28: Global meningococcal polysaccharide vaccine Market Volume (K) By Region

Figure 29: Global meningococcal polysaccharide vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global meningococcal polysaccharide vaccine Market Value (USD Million) By Region

Figure 37: Global meningococcal polysaccharide vaccine Market Share (%) By: Regions (2032)

Figure 38: Global meningococcal polysaccharide vaccine Market Volume (K) By Region

Figure 39: Global meningococcal polysaccharide vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global meningococcal polysaccharide vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global meningococcal polysaccharide vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global meningococcal polysaccharide vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global meningococcal polysaccharide vaccine Market Value (USD Million) By Region

Table 14: Global meningococcal polysaccharide vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global meningococcal polysaccharide vaccine Market Volume (K) By Region

Table 31: Global meningococcal polysaccharide vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global meningococcal polysaccharide vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global meningococcal polysaccharide vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global meningococcal polysaccharide vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Basic Information And Sales Area

Table 52: Sanofi. Products Portfolio

Table 53: Bio-Med Basic Information And Sales Area

Table 54: Bio-Med. Products Portfolio

Table 55: CanSinoBIO Basic Information And Sales Area

Table 56: CanSinoBIO. Products Portfolio

Table 57: Walvax Biotechnology Basic Information And Sales Area

Table 58: Walvax Biotechnology. Products Portfolio

Table 59: Chongqing Zhifei Biological Basic Information And Sales Area

Table 60: Chongqing Zhifei Biological. Products Portfolio

Table 61: Chengdu Kanghua Biological Products Basic Information And Sales Area

Table 62: Chengdu Kanghua Biological Products. Products Portfolio

Table 63: Changsheng Biotechnology Basic Information And Sales Area

Table 64: Changsheng Biotechnology. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global meningococcal polysaccharide vaccine Market Value (USD Million) By Region

Table 74: Global meningococcal polysaccharide vaccine Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global meningococcal polysaccharide vaccine Market Volume (K) By Region

Table 91: Global meningococcal polysaccharide vaccine Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

meningococcal polysaccharide vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Bio-Med; CanSinoBIO; Walvax Biotechnology; Chongqing Zhifei Biological; Chengdu Kanghua Biological Products; Changsheng Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Competition from conjugate vaccines, which offer improved immunological efficacy in children, is reducing the relative demand for polysaccharide-based products, particularly in pediatric segments.

Opportunities2 items

Advancements in adjuvant technologies and conjugation techniques may enable the development of hybrid vaccines, bridging the efficacy gap with conjugate vaccines while retaining cost advantages.

Challenges2 items

Regulatory scrutiny remains a key hurdle, with evolving guidelines on serotype coverage and immunogenicity thresholds requiring frequent reformulation and clinical revalidation.

Price erosion in mature markets due to generic competition and bulk procurement contracts is compressing profit margins, forcing manufacturers to innovate or diversify into niche vaccine segments.

Market Segmentation

Loading chart…

meningococcal polysaccharide vaccine Segmentation Breakdown8 items

Application

6 Months-15Year

over 3 Year

over 2 Year

over 3 Months

Types

Polysaccharide Meningtitis AC

Meningitis ACYW

Regional Insights

Loading chart…

Competitive Landscape

Sanofi: Innovation pipeline for broad-spectrum conjugate vaccines

Bio-Med: Regional expansion in Asia-Pacific through OEM tie-ups

CanSinoBIO: Premium pricing for advanced serogroup B formulations

Walvax Biotechnology: Vertical integration for cost advantages

Chongqing Zhifei Biological: Local manufacturing for emerging markets

Chengdu Kanghua Biological Products: Channel partnerships for rural penetration

Key meningococcal polysaccharide vaccine Companies7 items

Sanofi

Bio-Med

CanSinoBIO

Walvax Biotechnology

Chongqing Zhifei Biological

Chengdu Kanghua Biological Products

Changsheng Biotechnology

Market Ecosystem

Raw material suppliers — provide purified meningococcal polysaccharides, adjuvants, and stabilizers for vaccine formulation

Vaccine manufacturers — conduct antigen conjugation, fill-finish processes, and quality assurance testing

Technology providers — license proprietary conjugation techniques or purification systems for production scalability

Distributors — manage temperature-controlled transportation and storage to prevent potency degradation

Regulatory bodies — enforce approval pathways and post-market surveillance for safety and efficacy

Healthcare providers — administer vaccines to pediatric and high-risk populations per immunization schedules

Service providers — offer cold-chain monitoring systems and digital inventory tracking for supply chain transparency

Recent Industry Insights

Analyst Overview

Table of Contents